Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Tarantula Venom May be New Hope for Painkillers

By Drug Discovery Trends Editor | February 14, 2014

(Source: Yale University)Screening more than 100 spider toxins, Yale researchers identified a protein from the venom of the Peruvian green velvet tarantula that blunts activity in pain-transmitting neurons. The findings, reported in the journal Current Biology, show the new screening method used by the scientists has the potential to search millions of different spider toxins for safe pain-killing drugs and therapies.
 
The researchers note that they tested the spider toxins on only one of a dozen suspected human pain channels.
 
“The likelihood is that within the vast diversity of spider toxins we will find others that are active against other channels important for pain,” said Michael Nitabach, associate professor of cellular and molecular physiology and of genetics, and senior author of the paper.
 
The researchers screened the toxins from a variety of tarantula species to find one that blocked TRPA1, an ion channel on the surface of pain-sensing neurons that is implicated in inflammation and neuropathic pain.
 
In a process dubbed toxineering by the Yale researchers, the team generated another small library of mutated versions of the tarantula toxin to find one that blocked TRPA1 but had no effect on activity of other channels on the surface of neurons.
 
“The beauty of the system is we can also screen engineered toxins not found in nature, and identify higher-potency and more specific molecular variants that lack deleterious effects on essential nerve functions,’’ Nitabach said.
 
His lab plans to ramp up efforts to test tens of thousands of new toxins for similar biological activity against pain-sensing neurons.
 
Date: February 13, 2014
Source: Yale University

Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE